A selected small molecule prevents inflammatory osteolysis through restraining osteoclastogenesis by modulating PTEN...

Area of Science:

• Biomedical Science
• Pharmacology
• Orthopaedics

Background:

• Inflammatory osteolysis is a severe bone disorder complicating orthopaedic surgery.
• It arises from disrupted bone homeostasis and excessive osteoclast activity.
• Inhibiting osteoclastogenesis is a key strategy for preventing bone destruction.

Purpose of the Study:

• To investigate the therapeutic potential of compound 17 against inflammatory osteolysis.
• To elucidate the mechanisms underlying compound 17's effects on osteoclastogenesis and inflammation.

Main Methods:

• In vitro studies assessed compound 17's effects on osteoclast differentiation and bone resorption.
• A lipopolysaccharide (LPS)-induced mouse model evaluated compound 17's in vivo efficacy.
• Mechanistic studies explored compound 17's impact on PTEN activity, NF-κB signaling, and macrophage polarization.

Main Results:

• Compound 17 dose-dependently inhibited osteoclast differentiation and bone resorption.
• It promoted phosphatase and tensin homologue (PTEN) activity, suppressed the NF-κB pathway, and reduced osteoclastogenesis-related gene expression.
• Compound 17 demonstrated anti-inflammatory effects, modulated macrophage polarization, and supported osteoblast differentiation.
• In vivo, compound 17 protected against LPS-induced bone destruction by inhibiting osteoclastogenesis and inflammation.

Conclusions:

• Compound 17 exhibits protective effects against inflammatory bone destruction.
• It acts by inhibiting osteoclastogenesis and inflammation, suggesting therapeutic potential for inflammatory osteolysis-related diseases.